Table 3. Correlation between clinicopathological variables and PLA2G16 expression in 94 HER2-positive cases.
| Variables | Number of patients (%) | PLA2G16 | Pa | |
|---|---|---|---|---|
| Low expression N (%) | High expression N (%) | |||
| Total | 94 | |||
| Age | 0.847 | |||
| ≤50 years | 50 | 26 (27.7) | 24 (25.5) | |
| >50 years | 44 | 22 (23.4) | 22 (23.4) | |
| Menstrual status | 0.398 | |||
| Premenopausal | 51 | 24 (25.5) | 27 (28.7) | |
| Postmenopausal | 43 | 24 (25.5) | 19 (20.2) | |
| Tumor size | 0.066 | |||
| ≤2 cm | 31 | 14 (14.9) | 17 (18.1) | |
| >2, ≤5 cm | 56 | 32 (34.0) | 24 (25.5) | |
| >5 cm | 4 | 0 (0.0) | 4 (4.3) | |
| NA | 3 | 2 (2.1) | 1 (1.1) | |
| Lymph node status | 0.697 | |||
| Negative | 41 | 20 (21.3) | 21 (22.3) | |
| Positive | 53 | 28 (29.8) | 25 (26.6) | |
| Grade | 0.306 | |||
| I | 70 | 34 (36.2) | 36 (38.3) | |
| II | 23 | 14 (14.9) | 9 (10.0) | |
| NA | 1 | 0 (0.0) | 1 (1.1) | |
| ER status | 0.021 | |||
| Negative | 60 | 36 (38.3) | 24 (25.5) | |
| Positive | 34 | 12 (12.8) | 22 (23.4) | |
| PR status | 0.619 | |||
| Negative | 61 | 30 (31.9) | 31 (33.0) | |
| Positive | 33 | 18 (19.1) | 15 (16.0) | |
a, based on Pearson’s χ2 test. ER, estrogen receptor; PR, progesterone receptor; HER-2, human epidermal growth factor receptor 2; PLA2G16, Group XVI phospholipase A2; NA, not available.